Background: Bleomycin is an integral part of combination chemotherapy in germ cell tumours. Pulmonary toxicity often necessitates drug cessation and death occurs in 1%-2% of patients. A continuous infusion of bleomycin might reduce lung toxicity when compared with the conventional weekly boluses given as part of standard BEP chemotherapy.
Introduction
Most patients with IGCCCG good prognosis metastatic germ cell tumours are cured with three cycles of cisplatin, etoposide and bleomycin (BEP). Randomized studies have confirmed cisplatin 100 mg/m 2 , etoposide 500 mg/m 2 and bleomycin 90 000 units per cycle to be optimal [1, 2] . The cisplatin and etoposide may be given over 3 or 5 days [2] and reductions in the dosage of bleomycin or etoposide are associated with poorer overall survival [1, 3] . Bleomycin has long been known to cause unpredictable and occasionally fatal lung toxicity. Prior poor lung function, a smoking history, and impaired renal function may predispose to an increased likelihood of toxicity [4] . Retrospective reports suggest that the damage caused by bleomycin be related to the peak levels of the drug which may be avoided by giving the drug as a continuous infusion [5] . In vivo experiments in animal models support this hypothesis [6] .
In a patient group with a good outcome, optimization of bleomycin may be expected to improve efficacy and reduce toxicity. As the value of pulmonary function testing in this setting has been controversial [7] we wished to see whether pre-treatment pulmonary function testing could identify an at-risk population for development of lung toxicity and whether changes during treatment correlated with the development of CT scan changes. We also wished to determine whether any symptoms associated with the development of bleomycin induced lung injury, e.g. shortness of breath, cough, and chest discomfort correlated with CT changes. We therefore carried out a randomized trial.
Patients and methods
Eligible patients were males over 16 years old with IGCCCG good prognosis disease (testicular germ cell tumours with metastases but no nonpulmonary visceral sites with tumour markers not exceeding the following AFP 1000 ng/ml, hCG, 5000 iU/ml, LDH 1.5Â the upper limit of normal).
All patients were staged using CT scanning. The pulmonary parenchyma was assessed using conventional lung settings rather than dedicated high resolution CT of the chest. Patients were required to have adequate renal function (calculated or measured glomerular filtration rate of >50ml/min). Patients were randomized to receive 3 cycles of 3 day BEP (cisplatin 50 mg/m 2 on days 1 and 2, etoposide 166 mg/m 2 days 1, 2 and 3) and either conventional bleomycin 30 000 units per week on days 1, 8 and 15 as a 30-min i.v. infusion (conventional arm) or a protracted infusion (90 000 units as a continuous i.v. infusion over 3 days on days 1, 2 and 3 of each cycle (infusional arm). Routine use of growth factors was not permitted. A conventional chest CT, quality of life, and pulmonary function tests were carried out immediately before the second cycle, at the end of treatment (9 weeks after chemotherapy started), 1 and 2 years after treatment.
Quality of life assessments used the EORTC QLQC-30 questionnaire with the addition of LC 17 (originally developed for lung cancer, it was used to look for specific symptoms attributable to lung toxicity) [8] .
The primary end point of the study was the development of CT assessed lung toxicity attributable to bleomycin. The validated endpoint CT changes were selected, as they, rather than changes in lung function correlate best with long term pulmonary damage [4, 9, 10] . The secondary endpoints were progression-free survival (PFS), overall survival, changes in pulmonary function testing, and quality of life. Pulmonary function tests included an assessment of FEV1, FVC, TlCO and KCO.
Patients were required to give written informed consent. The trial had formal ethical approval (trial reg MREC 3/3/029).
CT review
All the CT scans were anonymized, the reporting radiologist was blinded to treatment allocation and all scans viewed by a single radiologist. The scans were reported as follows. As this was a multicentre trial, scan acquisition varied according to institution, but in all cases, slice thickness was no more than 2.5 mm. Where dedicated lungs settings were not provided, a standard edge algorithm was applied. Each lung field was split into an anterior and posterior section (4 in all right anterior, right posterior, left anterior and left posterior). The degree of CT assessed lung toxicity was graded between 0 and 3. Grade 1 changes represented subtle fine subpleural linear opacity, grade 2 changes-more pronounced than grade 1 but with no coalescence or consolidation. Grade 3 represented more diffuse changes with coalescence [11] . The number or total sections with subpleural changes for each scan examined was noted allowing a percentage of sections with involved changes to be derived, as well as the proportion of grade 2 and 3 changes. The results were summarized in the following format-the percentage of sections showing any damage, the number of sections showing individually grade1, 2 or 3 damage. This was carried out at baseline, day 21, end of treatment and 1 and 2 years posttreatment. In some patients changes were present before chemotherapy-these were termed baseline changes, their subsequent presence post-chemotherapy were therefore not attributable to bleomycin.
Statistics
A previous retrospective review of the toxicity encountered when bleomycin was administered as a continuous infusion had suggested a substantial reduction in bleomycin induced changes (a difference of 44%). It was felt to be worthwhile even if the reduction in toxicity were around 15%. Therefore, a reduction in toxicity from 27% (expected) to 11% required a total of 210 patients at the 5% level of significance with 80% power based on a two-sided test.
Randomization, following 1 : 1 allocation, was stratified for smoking (smoker versus non-smoker), renal dysfunction (>80 ml/min or 80 ml/min as calculated by Cockroft and Gault) and age (<30 versus !30 years) as all these factors have been associated with an increased risk of bleomycin induced lung toxicity [4, 12] .
To determine the statistical significance of the association between categorical and continuous outcome variables, the v 2 and independent samples t-test were used as appropriate. Repeated measures mixed effects models were used to model CT proved lung toxicity as a function of the predictor variables accounting for both fixed effects (stratification factors) and random effect (patient ID). Non-parametric testing for trend was carried out to observe for trends in toxicity grading with time. Pearson's correlation coefficients were used to assess correlation between lung function variables and lung toxicity at each time point and then linear regression was used for prediction. Association between quality of life (symptoms) and change of lung toxicity (end of treatment-baseline) was studied using two-sample t-test.
Results
Two hundred and twelve patients from 13 sites were randomized (105 in the infusional arm and 107 in the conventional arm), see CONSORT diagram in supplementary Figure S1 , available at Annals of Oncology online. Table 1 confirms the validity of randomization with the two groups well balanced in terms of baseline characteristics. Thirty-five percent of patients were smokers, 5% had an estimated GFR of <80 ml/min and 53% were over the age of 30. The median follow-up was 2.3 years.
The proportion of patients with CT detected lung toxicity (any, grade !2, grade 3), respectively, increased from baseline (12.2%, 0%, 0%) to day 21 (29.5%, 2%, 0%) and end of treatment (705%, 34.5%, 5.1%) but improved at 1 year post-treatment (52.4%, 4.2%, 0.6%) and 2 years post-treatment (47.9%, 2.6%, 0.9%). There was a significant trend for increasing CT defined toxicity after 1 cycle, which peaked at the end of treatment (P 0.002).
Thirty percent of patients (n ¼ 37) had CT assessed grade 1 toxicity by day 21 and 35% of them increased to grade !2 toxicity by the end of the treatment. Eighty four (68%) patients showed no evidence of lung toxicity at day 21 but 27% of them went on to develop grade !2 lung toxicity at the end of treatment.
Those patients with smaller body surface areas (< median) did not have significantly higher toxicity (small BSA: 38% versus higher BSA: 34%, P ¼ 0.18) at the end of treatment despite the fact that bleomycin dosing was fixed independently of body size. Table 2 shows that toxicity in the infusional arm was generally higher than the conventional arm and it was significantly higher at the end of treatment (80% versus 62%, P ¼ 0.01).
Treatment comparison
Repeated measures mixed effects analysis, Table 3 ,
Smoking was not associated with baseline damage (P ¼ 0.5), nor was it related to the severity and frequency of subsequent bleomycin toxicity (Table 3 ). The total dose of bleomycin was the same in both groups.
Two-year PFS rate (infusional arm¼ 92.5% versus conventional arm ¼ 94.1%; hazard ratio ¼0.91, 95% CI 0.33-2.52) was not significantly different.
Lung function and CT assessed toxicity
There was no relationship between pre-existing lung function and subsequent CT assessed toxicity (see Table 4 ). Pulmonary function declined during treatment and then recovered 1 year post-therapy (supplementary Figure S2 , available at Annals of Oncology online). Table 4 shows that decreased lung function was weakly correlated (r % À0.30) with increased toxicity only at the end of treatment (P <0.05), especially based on DLCO (kco). Pre-treatment lung function did not predict subsequent development of pulmonary toxicity (all CIs include 0) (supplementary Table S1 , available at Annals of Oncology online).
Quality of life
The quality of life data showed that the development of a dry cough (P ¼ 0.002) rather than shortness of breath (P ! 0.09) or chest tightness (P ¼ 0.18) was the only symptom significantly associated with the development of CT assessed lung toxicity. Shortness of breath showed a positive association with the development of CT assessed lung toxicity but was not significant (P ¼ 0.09) (see Table 5 ).
Discussion
A continuous infusion of bleomycin over 72 h was unable to reduce the likelihood of developing pulmonary toxicity compared with conventional administration. There was significantly higher level of grade !2 toxicity in patients in the infusion arm, refuting the above hypothesis. Nevertheless this study has expanded our knowledge as to the timing of development of lung toxicity and the natural history of its resolution.
There was no suggestion that efficacy was increased by this approach despite animal models suggesting otherwise [6] . Supporting this conclusion, an in vivo study based on heterotransplanted testicular cancer cell lines found no significant difference in anti-tumour activity or toxicity on histological examination between continuous or bolus application of bleomycin where the same cumulative doses were compared [11] . Pulmonary toxicity from bleomycin may be related to peak levels and one weakness of this study was failure to measure these-it is possible that the infusion produced higher levels than anticipated and that a more prolonged infusion might have reduced toxicity.
This was a pragmatic study-high resolution CT scanning was not used to assess pulmonary toxicity on the basis that we were not looking for a test to be more sensitive but wanted to assess clinically more relevant changes. It could be argued that the varying scan protocols and acquisition parameters could have obscured significant differences, but the within-institution randomization ensured that such bias was minimized. Similarly, The results in bold attained a conventional level of significance (P<0.05).
subtle changes attributable to bleomycin could have been obscured by normal hypostatic changes, since prone scans were not routinely acquired, but this would be expected to affect subjects in both arms equally and the fact that serial scans were obtained in each patient minimized the likelihood of changes being missed or misinterpreted. Whilst intra-observer variability was controlled for by-re-reporting of blinded scans-a weakness of having only one radiologist reporting all the scans was that the potential role of inter-observational error could not be assessed.
The finding of changes, progressing until the end of treatment and then regressing, offers an opportunity for using early changes as a warning for more severe damage if bleomycin is continued. A recent study confirmed a similar pattern of change in lung damage as seen in TE3 with most of the changes in lung function reversing within 1 year of treatment [13] . They, however, used changes in diffusion capacity to reduce or omit bleomycin which they felt did not reduce survival. Their study differed in that it included poor and intermediate prognosis patients who would have received four cycles of bleomycin. This may be important as many of the factors thought to be associated with subsequent pulmonary toxicity were not borne out in our study. Neither baseline pulmonary, nor smoking history, nor renal function predicted toxicity; however, in the case of renal function, most (92%) had an estimated glomerular filtration rate of >80 ml/min, so although no association was noted it might simply suggest that only significantly impaired renal function increased bleomycin toxicity.
Bleomycin lung toxicity remains unpredictable and can be fatal which can lead to dropping bleomycin to avoid risk. For three cycles of cisplatin and etoposide the absence of bleomycin was associated with a poorer survival [14] . It is unclear whether dropping bleomycin can be compensated for by the addition of a fourth cycle of cisplatin and etoposide. One study-underpowered to show a survival difference showed a 5% higher event rate in patients randomized to four cycles of cisplatin and etoposide [15] .
Pulmonary function testing was not useful to identify patients at risk of developing lung toxicity. It was stipulated in the study that no reductions in bleomycin dosage for asymptomatic changes in pulmonary function testing should be made. This is not the first time that the value of pulmonary function testing has been questioned [16] . This argues for the abandonment of routine pulmonary function testing, which may avoid patients having their bleomycin omitted.
In our study, early CT scanning after 1 cycle of treatment, rather than pulmonary function testing or smoking history, was best able to identify patients at risk of subsequent lung toxicity.
The symptom assessment questionnaire showed that cough rather than shortness of breath was the most important symptom to assess before administration of bleomycin and if this were noted in the absence of another cause, an early CT of the chest might be carried out before further administration of bleomycin to establish if pulmonary toxicity had occurred.
The number of treatment failures in each arm (6%) was less than seen in previous randomized studies in this population [1, 2] despite the fact that the median age group was higher (32 years) than in comparable studies. The low level of treatment delays and drug omissions may have been responsible for this. It is important to point out that the overall prevalence of bleomycin induced lung damage was relatively low due to the fact that the study only included patients with good prognosis disease. In patients with more pulmonary disease where the total doses of bleomycin would be greater, risks would likely be higher. In a review by Sullivan et al. [4] of patients treated, age, dose (>300 000 units) and renal dysfunction were associated with increased risk of damage.
Conclusions
Bleomycin induced lung damage in patients with good prognosis germ cell tumours occurs independently of the method of delivery. The study supports the abandoning of routine pulmonary function testing both to identify patients at risk or during treatment as a means of detecting deterioration in pulmonary function. Instead, symptoms, especially cough, leading to the early use of CT is preferred. A history of smoking may not be a reason to withhold bleomycin. Whether these findings extend to patients with more advanced disease remains undetermined. 
